CSTL Q4 2021 Earnings — Castle Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CSTLCastle Biosciences, Inc.

$805M

Q4 2021 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$25M+44.7% YoY

Gross Profit

$20M81.6% margin

Operating Income

-$15M-60.6% margin

Net Income

-$6M-25.7% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

+6.7%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$4M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$463M

Total Liabilities

$51M

Stockholders' Equity

$412M

Cash & Equivalents

$330M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$25M	$17M	+44.7%
Gross Profit	$20M	$15M	+39.8%
Operating Income	-$15M	-$3M	-400.4%
Net Income	-$6M	-$5M	-31.5%